Corcept Therapeutics Inc

Corcept insider buys reveal executive confidence amid legal risk, showing disciplined buying and long‑term optimism for investors.

CEO Joseph Belanoff sells 26k Corcept shares via a pre‑planned 10b5‑1 plan, after FDA approval of Lifyorli, yet the move signals routine liquidity, not a sell‑off.

Corcept insider trading: Guyer William’s recent buy‑sell cycle signals confidence and strategic liquidity management, hinting at potential upside if the pipeline progresses.

Insider moves in Corcept Therapeutics reveal portfolio rebalancing, not a red flag, amid muted market reaction and growing social‑media buzz.

James Wilson’s recent sale of 28,000 Corcept Therapeutics shares shows insiders are rebalancing, not signaling a downturn, amid a 15% monthly dip and a potential rebound from new drug pipeline progress.

Insider buying shows confidence in Corcept amid legal and market turmoil—2026 trades signal a stabilizing factor for investors navigating FDA and fraud challenges.

Corcept Therapeutics’ insider buying surge—140K shares per exec—signals confidence amid a steep 41% dip and class‑action lawsuit; investors weigh optimism vs. risk.

Corcept insider Wilson buys 100,000 shares amid earnings miss and regulatory hurdles, signaling cautious confidence in its Cushing’s drug pipeline.